William Blair Initiates Coverage on Solid Biosciences with Outperform Rating
William Blair has launched coverage of Solid Biosciences (SLDB) with an 'Outperform' rating, driven by optimism surrounding the company's Duchenne Muscular Dystrophy (DMD) asset, SGT-003. The analyst noted that recent biomarker data for the treatment has shown strength, providing a positive outlook for the drug's development trajectory. Investors are looking toward Q1 2027, when a key clinical data update is expected for SGT-003. While William Blair did not assign a specific price target, the initiation suggests confidence in the asset's potential to impact the DMD therapeutic landscape.
Tickers: $SLDB
Topics: Biotechnology Duchenne Muscular Dystrophy Stock Rating